Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza
New research from Sanofi Pasteur on respiratory syncytial virus (RSV), meningococcal disease, and influenza are going to be featured at IDWeek 2021, from Michaelmas to October 3, 2021, underscoring the company’s pledge to develop meaningful solutions for patients.
“As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We anticipate to sharing developments from our leading vaccines pipeline which underscore our ongoing commitment to uncovering insights which will help prevent severe infectious diseases at every stage of life, especially in diseases with an unmet need like respiratory syncytial virus.”
Underscoring the necessity for all infant protection in RSV
RSV may be a highly contagious virus that causes respiratory disease in infants, including lung infections like bronchiolitis and pneumonia.1 Illness coded as RSV specific bronchiolitis was found to be the leading explanation for hospitalization in infants under 12 months, consistent with a study of pediatric hospitalizations between 1997 and 2000.2 A study conducted from 2014 to 2015 showed 72% of infants hospitalized for RSV were previously healthy with no underlying conditions.3
Nirsevimab is being developed by Sanofi and AstraZeneca and is being evaluated because the first investigational long-acting antibody designed to assist prevent lower tract infection (LRTI) caused by RSV altogether infants from birth up to 12 months aged during their first RSV season.
The following data reinforce the necessity for a preventative option that would help to guard all infants with one dose for the whole RSV season:
Medically Attended Illness thanks to Respiratory Syncytial viral infection Among Infants within the us During the 2016-17, 2017-18, 2018-19, and 2019-20 Seasons: the necessity for all Infants Protection. Poster presentation number 1137.
The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower tract Infection. public speaking number 1106281.*
- AstraZeneca leads all development activity through initial approvals.
Evaluating the impact of vaccination for meningococcal disease
Meningococcal disease, which incorporates meningococcal meningitis, may be a rare but potentially deadly bacterial infection.4,5 Anyone can get meningococcal disease, but teens and young adults are among those that are at the very best risk for the infection.6,7 Although rare, meningococcal disease develops rapidly and may claim the lifetime of an otherwise healthy individual in as little together day after the primary symptoms appear.4,5 The CDC recommends a primary dose of the MenACWY vaccine at 11-12 years old and a second dose at 16 years old. Despite these recommendations, approximately half U.S. teens have missed the crucial second dose.8
In the U.S., MenQuadfi® Meningococcal (Groups A, C, Y, W) Conjugate Vaccine is given to people 2 years aged and older to assist prevent invasive meningococcal disease (including meningitis) caused by serogroups A, C, W, and Y of meningococcal bacteria.7 MenQuadfi doesn’t prevent serogroup B disease.9 the subsequent new research evaluates the long-term impact of MenQuadfi across various age groups:
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster to Adults > 59 Years aged (PNM-43489). Poster presentation number 1046.
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a booster in Adults and Adolescents Vaccinated Against Meningococcal Disease 3-6 Years Earlier (PNM-51872). Poster presentation number 3.
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine Naïve Participants Across a Broad Age Range (2-55 years) in Japan (PNM-51878). Poster presentation number 4.
Examining the connection between influenza and antibiotic resistance patterns
New analyses will examine the link between antibiotic resistance patterns and seasonal influenza, which can help inform targeted antimicrobial stewardship initiatives during influenza season.
In the U.S., MenQuadfi vaccine is given to people 2 years aged and older to assist prevent invasive meningococcal disease (including meningitis) caused by serogroups A, C, W, and Y of meningococcal bacteria. MenQuadfi doesn’t prevent serogroup B disease.
MenQuadfi® is approved by the ecu Commission (EC) for the prevention of Invasive Meningococcal Disease in individuals 12 months aged and older and is currently under review by several health authorities across the planet to assist meet local immunization efforts.
Nirsevimab is an investigational long-acting antibody designed to assist protect all infants for the RSV season. thanks to its extended half-life technology, nirsevimab is being investigated as one dose for all infants experiencing their first RSV season and infants with congenital heart condition or chronic lung disease entering their first and second RSV season.
Nirsevimab is an immunization designed to supply prophylactic RSV protection to all or any infants via an antibody given on to an infant to assist prevent LRTI caused by RSV. Monoclonal antibodies don’t require the activation of the system to assist offer rapid and direct protection against disease.
Nirsevimab has been granted breakthrough designation by four major regulatory agencies round the world. These include Breakthrough Therapy Designation by The China Center for Drug Evaluation under the National Medical Products Administration; Breakthrough Therapy Designation from the US Food and Drug Administration; access granted to the ecu Medicines Agency PRIority Medicines scheme; and Promising Innovation Medicine designation by the Medicines and Healthcare Products regulatory authority . Nirsevimab is currently under clinical investigation and its safety and efficacy haven’t been reviewed by any regulatory agency .
Sanofi is devoted to supporting people through their health challenges. We are a worldwide biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few that suffer from rare diseases and therefore the millions with long-term chronic conditions.
With quite 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions round the globe.
Source link: https://www.sanofi.com/